Mirogabalin versus pregabalin for diabetic peripheral nerve pain

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with diabetic peripheral neuropathic pain (age ≥40 and Toronto neuropathy score ≥6) will be assigned to take either mirogabalin or pregabalin daily for eight weeks with clinic visits at weeks 1, 2, 4, 6, and 8. Pain intensity, safety events, and patient-reported quality-of-life measures will be recorded throughout the treatment period. Key eligibility requires persistent neuropathic pain despite standard therapy and stable diabetes control (HbA1c ≤8.5%), while patients on opioids or with gabapentinoid allergy, pregnancy, cancer pain, or radiculopathy are excluded. The trial compares efficacy and tolerability head-to-head to determine differences in analgesia and central nervous system side effects.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults (≥40 years) with diabetic neuropathy (Toronto score ≥6).
* Persistent pain (NPS) despite standard therapy.
* Stable diabetes management (HbA1c ≤8.5%).

Exclusion Criteria:

* History of drug allergy to gabapentinoids.
* Concurrent use of opioids or other neuropathic pain medications.
* Pregnancy or lactation.
* Cancer pain
* Entraptment Radioculopathy

Where it's running

• Bangladesh Medical University
  Dhaka, Bangladesh Recruiting

Study contacts

• Study coordinator: Kazi Mahzabin Arin, MD
• Email: kazimahzabinarin@bsmmu.edu.bd
• Phone: +8801754057689

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YJ001 Spray for Diabetic Nerve Pain in Feet

  This trial tests whether YJ001 Spray can help with diabetic peripheral neuropathic pain in adults, while also checking its safety.

  Recruiting Phase 3 Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. · Beijing, Haidian District · NCT07859111

• Entecavir 0.5 mg vs 1.0 mg daily in adults with HBV-related decompensated cirrhosis

  This trial tests whether 0.5 mg or 1.0 mg of entecavir once daily can better lower HBV DNA in adults with HBV-related decompensated cirrhosis over 24 weeks.

  Recruiting Phase 4 Bangladesh Medical University · Dhaka, Dhaka Division · NCT07816094

• Allopurinol to prevent complications in decompensated liver cirrhosis

  This trial tests whether allopurinol can reduce complications in adults with decompensated cirrhosis.

  Recruiting at 2 sites Phase 4 Bangladesh Medical University · Dhaka, Shahbagh and 1 other locations · NCT07800598

• ZEPU AI9 lower-limb exoskeleton gait training for walking difficulties

  This study tests whether the ZEPU AI9 exoskeleton can be safely and effectively added to standard rehabilitation to improve walking for adults with stroke, incomplete spinal cord injury, or gait problems after orthopedic surgery.

  Recruiting Bangladesh Medical University · Dhaka · NCT07750808

• Robot-assisted training for arm and leg movement after stroke or injury

  This study tests whether adding ZEPU-AI robotic training to usual therapy is safe and helps adults with arm or leg movement problems from stroke, spinal cord injury, brain injury, or orthopedic conditions.

  Recruiting Bangladesh Medical University · Dhaka · NCT07749625

• ZEPU-2000 robotic rehab for arm and leg weakness

  This trial tests whether adding ZEPU-2000A, ZEPU-2000D, and ZEPU-2000E robotic rehabilitation to usual therapy helps adults with arm/leg movement problems from stroke, incomplete SCI, TBI, or related conditions.

  Recruiting Bangladesh Medical University · Dhaka · NCT07749612

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.